Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

ents, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

Third Quarter Highlights and Recent Developments

-- Expanded Development Program for R3487/MEM 3454 with Roche. In September 2008, Memory Pharmaceuticals and Roche amended their nicotinic alpha-7 receptor agonist agreement, resulting in accelerated milestone payments to the Company. The companies agreed to expand the ongoing Phase 2 study of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS) to provide for a more robust data set and increase the potential for the study to facilitate advancing the compound into a pivotal trial. The Company received $3.5 million in connection with the amendment and will receive $5.0 million upon the enrollment of the 212th patient in the trial, which is expected to occur in November 2008. An additional $8.5 million will become due 30 days following the availability of top-line data from the Phase 2 CIAS trial. In addition, Roche has agreed to fund all internal and external costs associated with expanding the trial.

-- Received Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908. In October, Memory Pharmaceuticals announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists including R3487/MEM 3454 and R4996/MEM 63908. The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

-- Completed Phase 1 Program for R4996/MEM 63908. In September, the Company completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The trial is the fourth and final study in the Company's Phase 1 program for the compound. The Company expects to announce top-line results from the entire Phase 1 program in the fourth quarter of 2008.

-- Presentations at Scientific Meeting
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... (NASDAQ: ANPI , TSX: ANP), a global ... participate in the Bank of America,2008 Health Care ... Las Vegas,Nevada., Dr. William Hunter, Angiotech,s President ... Wednesday, May 14, beginning at approximately,4:00 pm Pacific ...
... Informed Clinical Sciences (ICS) Advisory,Services Corporation announced ... Property (IP) platform. This Platform suite offers ... an Alliance Business,Review, and a Health IT ... concerns, and enabling technologies underlying the growth ...
... VIAP ), a biotechnology company focused on the ... today that,James G. Stewart, senior vice president and chief ... & Renshaw 5th Annual Global,Healthcare Conference on Monday, May ... Plaza Hotel in Monte Carlo, Monaco., ...
Cached Biology Technology:IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 2IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 3
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... of an animal food protein to a human protein determines ... scientists from the Institute of Food Research in Norwich and ... have the potential to become allergens, but the study found ... act as allergens depends on their evolutionary distance from a ...
... molecular pathway that plays a critical role in the ... an important insight into the development of the vascular ... for inhibiting the blood vessels that fuel cancers, diabetic ... study, published online on Oct. 14 in Nature Genetics. ...
... Lake Tahoe, CA, October 13, 2007Today at the Prostate ... findings on how eating common foods such as tomatoes ... cooked at high temperatures may help prevent prostate cancer, ... One in six men will be diagnosed with ...
Cached Biology News:Animal food allergens unmasked 2Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: